These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 11904974

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 4. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S.
    Semin Oncol; 1999 Aug 18; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [Abstract] [Full Text] [Related]

  • 5. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA.
    Am J Ther; 2005 Aug 18; 12(3):243-53. PubMed ID: 15891269
    [Abstract] [Full Text] [Related]

  • 6. [Trastuzumab (Herceptin)].
    Tokuda Y, Suzuki Y, Saitou Y, Ohta M, Tajima T.
    Gan To Kagaku Ryoho; 2002 Apr 18; 29(4):645-52. PubMed ID: 11977556
    [Abstract] [Full Text] [Related]

  • 7. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, Cremoux PD, Couturier J, Palangié T, Pouillart P.
    Bull Cancer; 1999 Jun 18; 86(6):544-9. PubMed ID: 10417428
    [Abstract] [Full Text] [Related]

  • 8. [Herceptin-based therapy for breast cancer].
    Tokuda Y, Saito Y, Suzuki Y.
    Nihon Rinsho; 2006 Mar 18; 64(3):540-5. PubMed ID: 16529047
    [Abstract] [Full Text] [Related]

  • 9. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S, Pickering L, Ellis P.
    J Br Menopause Soc; 2006 Dec 18; 12(4):172-4. PubMed ID: 17178019
    [Abstract] [Full Text] [Related]

  • 10. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W, Esteva FJ.
    Eur J Cancer; 2008 Dec 18; 44(18):2806-12. PubMed ID: 19022660
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT, Lee TW, Lo JM.
    Nucl Med Biol; 2009 May 18; 36(4):355-61. PubMed ID: 19423002
    [Abstract] [Full Text] [Related]

  • 13. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M.
    Hematol Oncol Clin North Am; 2007 Apr 18; 21(2):239-56. PubMed ID: 17512447
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L.
    Semin Oncol; 1999 Aug 18; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [Abstract] [Full Text] [Related]

  • 15. Ongoing and planned adjuvant trials with trastuzumab.
    Perez EA, Hortobagyi GN.
    Semin Oncol; 2000 Dec 18; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
    [Abstract] [Full Text] [Related]

  • 16. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN.
    Semin Oncol; 2001 Dec 18; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [Abstract] [Full Text] [Related]

  • 17. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S, Kim C, Wolmark N.
    N Engl J Med; 2008 Mar 27; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract] [Full Text] [Related]

  • 18. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM.
    Clin Ther; 1999 Feb 27; 21(2):309-18. PubMed ID: 10211534
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ.
    Oncologist; 2006 Sep 27; 11(8):857-67. PubMed ID: 16951389
    [Abstract] [Full Text] [Related]

  • 20. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
    Montemurro F, Aglietta M.
    Clin Breast Cancer; 2005 Apr 27; 6(1):77-80. PubMed ID: 15899075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.